This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

US News And World Report And Pharmacy Times Survey: Advil®, Centrum® And Robitussin® Are #1 Pharmacist Recommended

(NYSE: PFE) - U.S. News & World Report and Pharmacy Times, this week, published rankings of the Top Recommended Health Products, and Pfizer Consumer Healthcare (PCH) received top honors based on a recent survey of pharmacists across the U.S. The survey rankings showed Advil®, Centrum® and Robitussin® as the number one pharmacist recommended in each of their respective categories.

“At Pfizer Consumer Healthcare, we create safe and highly effective healthcare solutions designed to improve consumers’ lives,” said Brian Groves, Chief Marketing Officer at Pfizer Consumer Healthcare. “Pharmacists across the country play a critical role in providing healthcare counsel to consumers. To be recognized by this important group is an honor and proof that our commitment to quality and efficacy is our top priority when we develop and maintain our products.”

Advil®, which just kicked off its Advil® Relief in Action campaign that honors and supports volunteers, has been helping relieve pain for more than 25 years. Millions of people trust Advil® for unsurpassed relief of their aches and pains and PCH is proud to be recognized as #1 in the Oral Anti-Inflammatory category.

As the most-studied, most-recommended and most-preferred multivitamin brand in America, PCH is also pleased that Centrum® ranked #1 in the Multivitamins category, backed by over 30 years of nutritional expertise and science.

Robitussin® has reliably treated cough, cold and flu symptoms through a variety of different formulations tailored to fit different symptom combinations. The Robitussin® portfolio was recognized in five categories by U.S. News & World Report and Pharmacy Times, including the #1 ranking in the Cough/Cold/Flu Combinations – Liquid Formulations category.

Other Notable Pfizer Consumer Healthcare Product Rankings:

  • ThermaCare ® ranked first in the Thermal Relief Products category
  • Advil ® Cold and Sinus ranked first in the Cough/Cold/Flu Combinations - Daytime category
  • Preparation H® ranked first in the Hemorrhoidal Preparations category
  • Emergen-C® ranked second in the Immune Support category
  • Advil® ranked second in the Oral Arthritis Pain Relievers category
  • Caltrate® ranked second in the Calcium Supplements category
  • Chapstick ® ranked third in the Lip Balm category

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,102.36 -101.01 -0.55%
S&P 500 2,099.49 -8.29 -0.39%
NASDAQ 4,970.3590 -9.5420 -0.19%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs